Celgene reportedly in talks to buy Juno; Novartis' Kymriah receives fast-track reviews in U.S. and Europe; BI's Gilotrif gets expanded approval in lung cancer
Novartis Oncology taps Pfizer exec as CEO; healthcare jobs become the largest source of U.S. employment; HHS nominee wary about drug-pricing negotiations
Maker of Botox biosimilar Evolus files IPO; pharma execs expect major acquisitions in 2018; J&J and Bayer win Xarelto reversal verdict
Roche to buy Ignyta for $1.7 billion; FDA OKs Valeant eye drop for OTC sale; Kmart settles prescription drug fraud allegations
BI to pay $13.5 million for misleading marketing; ICER: CAR-T therapies more cost-effective than chemotherapy; FDA approves Roche's breast cancer combo therapy
Cancer Research UK's 'Right Now' brand campaign will return in 2018 with a new focus highlighting the impact that research has on people suffering with cancer.
FDA issues prescription drug promotion guidance; FDA approves first follow-on biologic of Lilly's Humalog; drugmakers allegedly hired nurses to promote drugs
FDA approves first nebulized LAMA COPD treatment; more than 2,000 cancer immunotherapies in development; FDA issues 3D-printing guidance
UnitedHealth Group to buy DaVita primary care unit for $4.9 billion; Roche drug combo doubles lung-cancer survival in trial; study: FDA programs expedite drug approval
U.K. to be first to sell OTC Viagra; Regeneron offers startup scientific expertise; docs more likely to get poor marks when they reject patient requests
J&J to hold meeting on maintaining Remicade market share; Acorda ends development of Parkinson's drug; Darzalex notches positive first-line results
FDA approves first digital pill; biotech companies race to develop cancer-fighting microbiome drugs; Loxo and Bayer reach $1.55 billion deal for rare cancer drugs
AstraZeneca sales fall on generic competition; Anthem broadens access for Duchenne muscular dystrophy drug; researchers are developing new biopsy techniques
Senator investigates Alkermes' opioid-marketing tactics; FDA approves Roche cancer drugs; CVS to launch next-day delivery nationwide
Pfizer Q3 revenue driven by Prevnar sales; President Trump's opioid panel presents draft to combat crisis; Novartis seeks FDA approval for CAR-T therapy Kymriah
FDA develops resources about biosimilars for HCPs; Biogen negotiates royalties for experimental Alzheimer's drug; GSK Q3 sales driven by HIV, respiratory drugs
The FDA approves Kite's CAR-T therapy; Omnicom reports strong Q3 performance for healthcare agencies; Hearst to acquire Rodale, up health presence
J&J reports 15% lift in pharma sales in Q3; Apple reportedly considers buying medical clinics; survey finds need for digital investment in payer marketing
Susan G. Komen and the Breast Cancer Research Foundation are focusing on raising awareness and research money for the deadliest forms of the disease.
Patients complain about positive healthcare ads; some drugmakers skirt Open Payment rules; new law requires disclosure of drug price hikes in California
DKMS worked with Marino on PR for the campaign and with Area 23 on its Comic Con booth.
The FDA wants to improve the generic drug approval process; Allergan CEO responds to criticism of patent deal; breast cancer death rate dropped 40%
Express Scripts' Miller says new models needed to pay for CAR-T; FDA warns about Intercept drug deaths; CVS puts limits on opioid scripts
The new brand campaign, Attacking Cancer from Every Angle, showcases all the services the organization provides.
The FDA approves first cancer biosimilar; it also approves Bayer's new lymphoma drug; clinical-trial participation for gynecological cancer drops
Teva names new CEO; Allergan transfers Restasis patent to skirt competition; Google invests in oncology
600 patients are eligible for CAR-T therapy; the FDA halts Keytruda combo study for multiple myeloma; the regulator delays decision on Herceptin biosimilar
The Swiss drugmaker is the first to receive FDA approval to market a CAR-T therapy.
The FDA approves Ironwood's gout drug; GSW names new president; Samsung and Takeda to partner on biologic development
Celgene's Revlimid tops the list, according to data compiled by EvaluatePharma.